Bruce Booth is a Partner in the Life Sciences group and joined Atlas Venture in 2005. He focuses on novel biopharmaceutical products, therapeutic platforms and innovative biomedical technologies.

Bruce currently serves on the Boards of Atlas portfolio companies Avila, Bicycle, Miragen, Nimbus, OnQity, ProtAffin and Zafgen.  He also works or has worked closely with portfolio companies ARCA Biopharma (NASD:ABIO), Archemix, NxStage Medical (NASD:NXTM), Prestwick (acquired by Biovail, Sept 2008), Proprius (acquired by Cypress Biosciences, Feb 2008), and Stromedix.

Previously, Bruce was an investor with Caxton Health Holdings and prior to that a consultant at McKinsey & Company.
As a British Marshall Scholar, Bruce earned a Doctorate in Molecular Immunology from the Oxford University, and received his Bachelor of Science degree summa cum laude in Biochemistry from the Pennsylvania State University.

He serves as a Trustee of the New York Academy of Medicine, where he participates on the Executive Committee as Treasurer.  He is also a member of UCB Pharma’s Scientific Advisory Board, among several other translational research advisory roles.

Bruce has authored numerous scientific papers and biotech venture capital review articles, including several in Nature Biotechnology and blogs about life science venture topics at LifeSciVC.com which is also syndicated with Forbes.

He lives in Wellesley, Massachusetts with his wife and three wonderful kids.